Turner And Klinefelter Treatment Target Study
Launched by DR. LAURA C. G. DE GRAAFF-HERDER · Mar 16, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Turner and Klinefelter Treatment Target Study is a clinical trial designed to understand how hormone levels affect the quality of life for patients with Turner Syndrome (TS) and Klinefelter Syndrome (KS). The study aims to explore the relationship between various hormone measurements and how these relate to feelings of well-being, energy, and stress in adults aged 18 and older with these conditions. Researchers will use questionnaires and blood tests to gather information, including hormone levels related to testosterone and thyroid function, to determine the best hormonal targets for improving overall quality of life in these patients.
To participate in this study, individuals must have a confirmed diagnosis of either Klinefelter or Turner syndrome, be at least 18 years old, and be able to read and understand Dutch. Participants will complete a series of questionnaires during visits to their healthcare provider, and some extra blood and hair samples will be collected. The study is currently recruiting, and it's important for interested patients to know that they should be under treatment at specific medical centers to be eligible. This research could provide valuable insights that might lead to better treatments and improved quality of life for individuals with these syndromes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Klinefelter or Turner syndrome as confirmed by genetic testing
- • Sufficient knowledge of the Dutch language to complete the questionnaires
- • At least 18 years old
- Exclusion Criteria:
- • KS: Patients not under treatment in the EMC, AMC or VUmc or no planned visits during the study period
- • TS: No laboratory values or no questionnaires available in patient records
- • Severe psychiatric or neurologic disorders or other reasons for inability to complete the questionnaires as assessed by the treating physician.
- • Failure to obtain informed consent
About Dr. Laura C. G. De Graaff Herder
Dr. Laura C. G. de Graaff-Herder is a distinguished clinical trial sponsor known for her commitment to advancing medical research and improving patient outcomes. With a strong background in clinical medicine and a focus on innovative therapeutic approaches, Dr. de Graaff-Herder leads initiatives that prioritize rigorous study design and ethical conduct. Her collaborative approach fosters partnerships with academic institutions and industry stakeholders, ensuring that trials are not only scientifically robust but also aligned with the needs of diverse patient populations. Through her leadership, she aims to contribute significantly to the body of knowledge in her field, enhancing the effectiveness and accessibility of healthcare interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rotterdam, Zuid Holland, Netherlands
Patients applied
Trial Officials
Laura de Graaff, MD, PhD
Principal Investigator
Department of Internal Medicine - Endocrinology, Erasmus MC, Rotterdam, the Netherlands
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials